Palo Alto Investors’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-278,985
| Closed | -$1.18M | – | 40 |
|
|
2023
Q4 | $1.18M | Hold |
278,985
| – | – | 0.11% | 28 |
|
|
2023
Q3 | $1.21M | Sell |
278,985
-45,088
| -14% | -$251K | 0.11% | 25 |
|
|
2023
Q2 | $2.14M | Sell |
324,073
-158,624
| -33% | -$1.02M | 0.17% | 23 |
|
|
2023
Q1 | $3.28M | Sell |
482,697
-604,910
| -56% | -$4.25M | 0.27% | 21 |
|
|
2022
Q4 | $8.04M | Sell |
1,087,607
-1,078,549
| -50% | -$10.5M | 0.69% | 17 |
|
|
2022
Q3 | $21.4M | Sell |
2,166,156
-325,044
| -13% | -$3.43M | 1.69% | 13 |
|
|
2022
Q2 | $27.2M | Hold |
2,491,200
| – | – | 2.37% | 11 |
|
|
2022
Q1 | $28.2M | Sell |
2,491,200
-343,044
| -12% | -$4.51M | 2.18% | 13 |
|
|
2021
Q4 | $44.5M | Sell |
2,834,244
-957,561
| -25% | -$16.7M | 2.84% | 11 |
|
|
2021
Q3 | $65M | Hold |
3,791,805
| – | – | 3.92% | 10 |
|
|
2021
Q2 | $81.6M | Hold |
3,791,805
| – | – | 4.49% | 10 |
|
|
2021
Q1 | $57M | Sell |
3,791,805
-438,743
| -10% | -$7.1M | 3.25% | 12 |
|
|
2020
Q4 | $55.6M | Buy |
4,230,548
+60,267
| +1% | +$725K | 2.91% | 13 |
|
|
2020
Q3 | $40.3M | Buy |
4,170,281
+53,733
| +1% | +$574K | 2.21% | 13 |
|
|
2020
Q2 | $47.1M | Sell |
4,116,548
-18,298
| -0.4% | -$207K | 2.83% | 14 |
|
|
2020
Q1 | $42.8M | Sell |
4,134,846
-390,630
| -9% | -$4.84M | 3.59% | 13 |
|
|
2019
Q4 | $74.3M | Sell |
4,525,476
-55,700
| -1% | -$842K | 4.09% | 13 |
|
|
2019
Q3 | $60.8M | Sell |
4,581,176
-473,874
| -9% | -$6.6M | 4.05% | 12 |
|
|
2019
Q2 | $71.2M | Hold |
5,055,050
| – | – | 3.46% | 14 |
|
|
2019
Q1 | $93M | Buy |
5,055,050
+899,380
| +22% | +$20.5M | 3.88% | 11 |
|
|
2018
Q4 | $109M | Hold |
4,155,670
| – | – | 5.78% | 6 |
|
|
2018
Q3 | $95.4M | Hold |
4,155,670
| – | – | 3.85% | 10 |
|
|
2018
Q2 | $79.2M | Hold |
4,155,670
| – | – | 3.16% | 13 |
|
|
2018
Q1 | $70M | Hold |
4,155,670
| – | – | 2.99% | 11 |
|
|
2017
Q4 | $63.2M | Hold |
4,155,670
| – | – | 2.72% | 11 |
|
|
2017
Q3 | $74.4M | Sell |
4,155,670
-47,600
| -1% | -$797K | 3.13% | 9 |
|
|
2017
Q2 | $68.5M | Hold |
4,203,270
| – | – | 3.2% | 11 |
|
|
2017
Q1 | $58.8M | Hold |
4,203,270
| – | – | 2.78% | 13 |
|
|
2016
Q4 | $67M | Buy |
4,203,270
+92,562
| +2% | +$1.49M | 3.82% | 9 |
|
|
2016
Q3 | $68.4M | Sell |
4,110,708
-114,900
| -3% | -$1.55M | 3.97% | 9 |
|
|
2016
Q2 | $47.3M | Buy |
4,225,608
+194,700
| +5% | +$1.89M | 3.57% | 7 |
|
|
2016
Q1 | $33.7M | Hold |
4,030,908
| – | – | 2.62% | 9 |
|
|
2015
Q4 | $37.5M | Buy |
4,030,908
+33,800
| +0.8% | +$337K | 2.09% | 13 |
|
|
2015
Q3 | $45.1M | Buy |
3,997,108
+99,700
| +3% | +$1.22M | 2.17% | 10 |
|
|
2015
Q2 | $49.5M | Buy |
3,897,408
+94,000
| +2% | +$1.01M | 2.2% | 12 |
|
|
2015
Q1 | $35.4M | Buy |
3,803,408
+16,500
| +0.4% | +$186K | 1.75% | 13 |
|
|
2014
Q4 | $54.2M | Buy |
3,786,908
+503,784
| +15% | +$5.96M | 3.18% | 12 |
|
|
2014
Q3 | $34.1M | Buy |
3,283,124
+42,700
| +1% | +$560K | 2.55% | 13 |
|
|
2014
Q2 | $52.4M | Buy |
3,240,424
+25,000
| +0.8% | +$333K | 3.9% | 8 |
|
|
2014
Q1 | $52.3M | Sell |
3,215,424
-23,200
| -0.7% | -$330K | 4.32% | 8 |
|
|
2013
Q4 | $40.2M | Buy |
3,238,624
+330,310
| +11% | +$3.32M | 3.75% | 11 |
|
|
2013
Q3 | $31.8M | Buy |
2,908,314
+526,438
| +22% | +$5.62M | 3.34% | 13 |
|
|
2013
Q2 | $19.2M | Buy |
+2,381,876
| New | +$16M | 2.27% | 13 |
|
Other funds holding VNDA
TCM
Palo Alto Investors's VNDA Position: Q1 2024 in Review
Palo Alto Investors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 278,985 shares — an estimated $1.18M sold.
Palo Alto Investors first reported a position in VNDA in Q2 2013 and held it in 43 quarters. The position peaked at $109M in Q4 2018. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.
- Palo Alto Investors reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
- Palo Alto Investors sold 278,985 Vanda Pharmaceuticals shares in Q1 2024, an estimated $1.18M.
- Palo Alto Investors first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 43 quarters.
- Palo Alto Investors's Vanda Pharmaceuticals position peaked at $109M in Q4 2018.
- 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.
Based on Palo Alto Investors's 13F filing for Q1 2024, filed 15 May 2024.